391 related articles for article (PubMed ID: 25204639)
1. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
3. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
6. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
8. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
9. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Alimohamed N; Daly A; Owen C; Duggan P; Stewart DA
Leuk Lymphoma; 2012 May; 53(5):862-7. PubMed ID: 22023529
[TBL] [Abstract][Full Text] [Related]
10. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
11. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
14. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM; Doorduijn JK; Re A; Cabras MG; Smith J; Ilariucci F; Luppi M; Calimeri T; Cattaneo C; Khwaja J; Botto B; Cellini C; Nassi L; Linton K; McKay P; Olivieri J; Patti C; Re F; Fanni A; Singh V; Bromberg JEC; Cozens K; Gastaldi E; Bernardi M; Cascavilla N; Davies A; Fox CP; Frezzato M; Osborne W; Liberati AM; Novak U; Zambello R; Zucca E; Cwynarski K;
Lancet Haematol; 2021 Feb; 8(2):e110-e121. PubMed ID: 33513372
[TBL] [Abstract][Full Text] [Related]
15. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
16. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.
Tanaka Y; Sakai T; Tsunemine H; Ito T; Arima N
J Clin Exp Hematop; 2024 Mar; 64(1):32-36. PubMed ID: 38417873
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
19. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
